|
| 37823865 | Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. | Clin Infect Dis | 2024 |
| 37947968 | Influence of Participant Perceptions of Adherence-Related Interactions with Study/Study Team on Drug Levels: HPTN069 Analysis of Self-Reported Adherence Experiences While on Study. | AIDS Behav | 2024 |
| 37823865 | Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. | Clin Infect Dis | 2024 |
| 37947968 | Influence of Participant Perceptions of Adherence-Related Interactions with Study/Study Team on Drug Levels: HPTN069 Analysis of Self-Reported Adherence Experiences While on Study. | AIDS Behav | 2024 |
| 36063243 | Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. | AIDS Behav | 2023 |
| 36063243 | Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. | AIDS Behav | 2023 |
| 37783219 | Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. | Lancet HIV | 2023 |
| 37418423 | Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. | AIDS | 2023 |
| 36842333 | Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. | J Pharm Biomed Anal | 2023 |
| 37344551 | Prevention, treatment and cure of HIV infection. | Nat Rev Microbiol | 2023 |
| 36642087 | Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. | Lancet HIV | 2023 |
| 37118968 | A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. | Clin Transl Sci | 2023 |
| 36995219 | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. | Antimicrob Agents Chemother | 2023 |
| 37116934 | Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. | Glob Health Sci Pract | 2023 |
| 36454551 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. | JAMA | 2023 |
| 36844011 | Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. | Lancet Reg Health Am | 2023 |
| 37783219 | Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. | Lancet HIV | 2023 |
| 37118968 | A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. | Clin Transl Sci | 2023 |
| 37418423 | Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. | AIDS | 2023 |
| 37116934 | Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. | Glob Health Sci Pract | 2023 |
| 37344551 | Prevention, treatment and cure of HIV infection. | Nat Rev Microbiol | 2023 |
| 36995219 | Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. | Antimicrob Agents Chemother | 2023 |
| 36844011 | Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. | Lancet Reg Health Am | 2023 |
| 36842333 | Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. | J Pharm Biomed Anal | 2023 |
| 36642087 | Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. | Lancet HIV | 2023 |
| 36454551 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. | JAMA | 2023 |
| 34791296 | Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. | J Antimicrob Chemother | 2022 |
| 36240386 | HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. | J Infect Dis | 2022 |
| 35762372 | Promises and challenges: cabotegravir for preexposure prophylaxis. | Curr Opin HIV AIDS | 2022 |
| 36026586 | Engagement With HIV and COVID-19 Prevention: Nationwide Cross-sectional Analysis of Users on a Geosocial Networking App. | J Med Internet Res | 2022 |
| 35949044 | A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP. | Br J Clin Pharmacol | 2022 |
| 35815468 | Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. | AIDS Res Hum Retroviruses | 2022 |
| 35695476 | Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. | Br J Clin Pharmacol | 2022 |
| 35943868 | Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. | AIDS Res Hum Retroviruses | 2022 |
| 35940869 | Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19. | J Med Virol | 2022 |
| 35687192 | Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). | AIDS Behav | 2022 |
| 35357767 | Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California. | J Viral Hepat | 2022 |
| 36053045 | Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. | Clin Trials | 2022 |
| 36714798 | A community-partnered approach for diversity in COVID-19 vaccine clinical trials. | J Clin Transl Sci | 2022 |
| 34791296 | Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. | J Antimicrob Chemother | 2022 |
| 35152299 | Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study. | Clin Infect Dis | 2022 |
| 35113892 | Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. | PLoS One | 2022 |
| 35099992 | Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. | Ann Intern Med | 2022 |
| 35006245 | Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. | JAMA Netw Open | 2022 |
| 35762372 | Promises and challenges: cabotegravir for preexposure prophylaxis. | Curr Opin HIV AIDS | 2022 |
| 35695476 | Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. | Br J Clin Pharmacol | 2022 |
| 35815468 | Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. | AIDS Res Hum Retroviruses | 2022 |
| 35357767 | Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California. | J Viral Hepat | 2022 |
| 35687192 | Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). | AIDS Behav | 2022 |
| 36714798 | A community-partnered approach for diversity in COVID-19 vaccine clinical trials. | J Clin Transl Sci | 2022 |